Kura Oncology (KURA) Shares Outstanding (Weighted Average) (2010 - 2026)

Kura Oncology (KURA) reported Shares Outstanding (Weighted Average) of $88.6 million for Q1 2026, up 1210.9% year-over-year from $6.8 million in Q1 2025, and up 1.07% on a QoQ basis from $87.7 million in Q4 2025.

Kura Oncology (KURA) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $88.6 million in Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) rose 1210.9% year-over-year to $88.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $88.6 million (up 1210.9% YoY) and the FY2025 annual result came in at $87.7 million, up 1197.09% from the prior year.
  • Shares Outstanding (Weighted Average) advanced to $88.6 million in Q1 2026 per KURA's latest filing, from $87.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Weighted Average) topped out at $88.6 million in Q1 2026 and bottomed at $840585.0 in Q3 2025.
  • The 5-year median for Shares Outstanding (Weighted Average) is $69.1 million (2023), against an average of $63.5 million.
  • The widest annual swing landed in 2024, when Shares Outstanding (Weighted Average) sank 96.97%; it then jumped 1210.9% in 2026.
  • Tracing KURA's Shares Outstanding (Weighted Average) over 5 years: stood at $67.0 million in 2022, then advanced by 9.31% to $73.2 million in 2023, then climbed by 17.66% to $86.2 million in 2024, then increased by 1.76% to $87.7 million in 2025, then climbed by 1.07% to $88.6 million in 2026.
  • Per Business Quant, the three latest KURA Shares Outstanding (Weighted Average) figures stand at $88.6 million (Q1 2026), $87.7 million (Q4 2025), and $840585.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Shares (Weighted Avg.) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 177,333.76 Bn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 185,491.37 Bn
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 100.00 Bn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 55.66 Bn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 118.76 Bn
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 254.10 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - 16.04 Bn
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 104.00 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 132.89 Mn
10 Kura Oncology 801.92 Mn 801.92 Mn 18.00 Mn 88.61 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 88.61 Mn
Dec 31, 2025 87.68 Mn
Sep 30, 2025 840,585.00
Jun 30, 2025 87.59 Mn
Mar 31, 2025 6.76 Mn
Dec 31, 2024 86.16 Mn
Sep 30, 2024 2.17 Mn
Jun 30, 2024 86.64 Mn
Mar 31, 2024 83.91 Mn
Dec 31, 2023 73.23 Mn
Sep 30, 2023 71.85 Mn
Jun 30, 2023 69.10 Mn
Mar 31, 2023 68.40 Mn
Dec 31, 2022 66.99 Mn
Sep 30, 2022 66.72 Mn
Jun 30, 2022 66.67 Mn
Mar 31, 2022 66.61 Mn
Dec 31, 2021 66.35 Mn
Sep 30, 2021 66.29 Mn
Jun 30, 2021 66.25 Mn
Mar 31, 2021 66.22 Mn
Dec 31, 2020 53.08 Mn
Sep 30, 2020 56.41 Mn
Jun 30, 2020 48.52 Mn
Mar 31, 2020 45.41 Mn
Dec 31, 2019 41.95 Mn
Sep 30, 2019 45.24 Mn
Jun 30, 2019 38.93 Mn
Mar 31, 2019 38.17 Mn
Dec 31, 2018 35.19 Mn
Sep 30, 2018 37.79 Mn
Jun 30, 2018 32.97 Mn
Mar 31, 2018 31.83 Mn
Dec 31, 2017 23.24 Mn
Sep 30, 2017 21.22 Mn
Jun 30, 2017 19.63 Mn
Mar 31, 2017 19.46 Mn
Dec 31, 2016 18.70 Mn
Sep 30, 2016 18.55 Mn
Jun 30, 2016 18.55 Mn
Mar 31, 2016 18.25 Mn
Dec 31, 2015 9.93 Mn
Sep 30, 2015 10.72 Mn
Jun 30, 2015 6.82 Mn
Mar 31, 2015 3.18 Mn
Dec 31, 2014 141,000.00
Sep 30, 2014 2,000.00
Jun 30, 2014 4.94 Mn
Mar 31, 2014 4.94 Mn
Dec 31, 2013 5.00 Mn
Sep 30, 2013 5.00 Mn
Jun 30, 2013 5.00 Mn
Mar 31, 2013 5.00 Mn
Dec 31, 2012 5.00 Mn
Sep 30, 2012 5.00 Mn
Jun 30, 2012 5.00 Mn
Mar 31, 2012 5.00 Mn
Dec 31, 2011 5.00 Mn
Sep 30, 2011 5.00 Mn
Jun 30, 2011 5.00 Mn
Mar 31, 2011 5.00 Mn
Dec 31, 2010 5.00 Mn
Sep 30, 2010 5.00 Mn